| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | New England Journal of Medicine | 2001 | 5.5K |
| Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control | Science | 1981 | 3.9K |
| Adipose tissue as an endocrine organ | Journal of Clinical Endocrinology and Metabolism | 2004 | 3.4K |
| Cellular and molecular mechanisms of fibrosis | Journal of Pathology | 2008 | 2.8K |
| The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes | New England Journal of Medicine | 2001 | 2.5K |
| A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury | Nature Medicine | 2005 | 2.3K |
| Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial | Lancet, The | 2003 | 2.1K |
| Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both | New England Journal of Medicine | 2003 | 1.9K |
| Angiotensin-converting enzyme 2 protects from severe acute lung failure | Nature | 2005 | 1.8K |
| Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system | Circulation | 1991 | 1.7K |
| Molecular basis of human hypertension: role of angiotensinogen | Cell | 1992 | 1.6K |
| An Overview of Heart Rate Variability Metrics and Norms | Frontiers in Public Health | 2017 | 1.6K |
| ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) | Circulation | 2004 | 1.6K |
| Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction | New England Journal of Medicine | 2004 | 1.5K |
| International union of pharmacology. XXIII. The angiotensin II receptors | Pharmacological Reviews | 2000 | 1.5K |
| Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system | American Journal of Physiology - Cell Physiology | 2007 | 1.4K |
| Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas | Proceedings of the National Academy of Sciences of the United States of America | 2003 | 1.4K |
| Molecular mechanisms of myocardial remodeling | Physiological Reviews | 1999 | 1.3K |
| Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis | Hepatology | 1988 | 1.2K |
| 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system | Journal of Clinical Investigation | 2002 | 1.2K |
| Physiology of local renin-angiotensin systems | Physiological Reviews | 2006 | 1.2K |
| Renin-angiotensin system: biochemistry and mechanisms of action | Physiological Reviews | 1977 | 1.2K |
| Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) | Circulation | 1990 | 1.2K |
| Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro | Cell | 1993 | 1.2K |
| Diabetic cardiomyopathy revisited | Circulation | 2007 | 1.2K |
